Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT00889252
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
contact lens with ketotifen, contact lens
Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Outcomes Associated With Application of a Normothermia Protocol in Patients With Severe Neurological Insult and Fever

NCT00890604
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Severe Traumatic Brain Injury
Interventions
Stepwise normothermia protocol, Ibuprofen, Acetominophen
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

NCT03713684
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide SAR439977, Placebo, Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 2 Interventional Results available

MLE4901 vs. Placebo for the Treatment of PCOS

NCT02865915
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
MLE4901, Placebo
Drug
Lead sponsor
Millendo Therapeutics US, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Oceanside, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 2Phase 3 Interventional

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

NCT06849973
View directory record Official record
Conditions
Rett Syndrome
Interventions
Drug: Bionetide, Placebo
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
5 Years to 20 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 4 Interventional

Nitrous Oxide for Analgesia During Office Urethral Bulking

NCT03847922
View directory record Official record
Conditions
Pain, Stress Incontinence, Female
Interventions
Nitrous Oxide + Oxygen Gas (Product), lidocaine gel 2%, Room air
Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks

NCT04050722
View directory record Official record
Conditions
Gingivitis
Interventions
Sensodyne Repair and Protect, Colgate Cavity Protection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

NCT00637494
View directory record Official record
Conditions
Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions
mifepristone, placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
22 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

NCT05832931
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 21, 2026, 3:57 AM EDT
Withdrawn Phase 2 Interventional

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

NCT02689713
View directory record Official record
Conditions
Pain, Thermal Injury, Burns, Hyperalgesia
Interventions
Voriconazole (topical), Topical Sterile Water Placebo Group
Drug
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects

NCT01757860
View directory record Official record
Conditions
Drug Safety, Heart; Disease, Activity
Interventions
CARD-024, Drug Carrier
Drug · Other
Lead sponsor
Cardiavent Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 21, 2026, 3:57 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Dapivirine Gel Rectal Safety and PK Study

NCT03044379
View directory record Official record
Conditions
HIV 1 Infection
Interventions
Dapivirine gel (0.05%), Universal HEC placebo gel
Drug · Other
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 21, 2026, 3:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

NCT05052996
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ISL, LEN, B/F/TAF, ISL/LEN FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

NCT06542497
View directory record Official record
Conditions
Presbyopia
Interventions
0.75% phentolamine ophthalmic solution, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
45 Years to 64 Years
Enrollment
569 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
39
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

NCT00582660
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 3:57 AM EDT
Active, not recruiting Phase 3 Interventional

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07368959
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions
Combination Product: AURN001 + Y-27632, Placebo
Drug · Other
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

NCT04909450
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

NCT00575159
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
GSK189075, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

NCT01029262
View directory record Official record
Conditions
Anemia
Interventions
Lenalidomide, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 21, 2026, 3:57 AM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05836220
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Anaheim, California • Chula Vista, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

NCT05806359
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danicamtiv, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 21, 2026, 3:57 AM EDT